Curevo Vaccine
About Curevo Vaccine
Curevo Vaccine is a clinical-stage biotechnology company focused on developing next-generation non-mRNA, adjuvanted subunit vaccines to address unmet medical needs. The company concentrates on targeted vaccine programs, starting with amezosvatein (CRV-101) for shingles and chickenpox, and aims to deliver effective, better-tolerated vaccines with scalable production. Based in Bothell, Washington, Curevo emphasizes rapid development and one-need-at-a-time strategy to bring vaccines to market efficiently.
Recent News
Lilly Gets Back in Infectious Disease, via Three M&A Deals
STAT+: Pharmalittle: We’re Reading About a Lilly Gene Therapy for Cholesterol, Three New Lilly Deals, and More
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
STAT+: Eli Lilly to Buy Three Small Vaccine Developers
The Biotech Bi-Weekly: Unveiling a New Brain Organoid Assay, Advancing Epigenomics Research and Building an Infectious Disease Research Portfolio
Lilly Just Bought Renowned Regulator Peter Marks a Pipeline to Play With
AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine
Eli Lilly to Acquire Curevo for up to $1.5 Billion, Boosting Shingles Vaccine Portfolio
Recent Deals
No recent deals for this company.